Getting Ahead Of IgAN: A New Treatment Paradigm For Disease Control Ft. Dr. Brad Rovin : 1 Rare Kidney Disease Show podcast

#Fitness #Podcasting Education #Medicine #Travere Therapeutics #Rare Kidney Disease #RKD #Travers #Igans #Fsgs

1:15:36

In this episode, we welcome back David French, columnist for The New York Times , former constitutional attorney, and author of Divided We Fall . We discuss the current state of American democracy, the challenges of political division, and how we can engage in civil discourse despite deep ideological differences. David also shares a personal update on his family and reflects on the profound trials and growth that come with adversity. 📌 What We Discuss: ✔️ How David and his family navigated the challenges of a serious health crisis. ✔️ The rise of political polarization and the factors driving it. ✔️ Why distinguishing between “unwise, unethical, and unlawful” is crucial in analyzing political actions. ✔️ How consuming different perspectives (even opposing ones) helps in understanding political dynamics. ✔️ The role of Christian values in politics and how they are being redefined. ⏳ Episode Highlights 📍 [00:01:00] – David French’s background and his journey from litigation to journalism. 📍 [00:02:30] – Personal update: David shares his wife Nancy’s battle with cancer and their journey as a family. 📍 [00:06:00] – How to navigate personal trials while maintaining faith and resilience. 📍 [00:10:00] – The danger of political paranoia and the pitfalls of extreme polarization. 📍 [00:18:00] – The "friend-enemy" paradigm in American politics and its influence in Christian fundamentalism. 📍 [00:24:00] – Revisiting Divided We Fall : How America’s divisions have devolved since 2020. 📍 [00:40:00] – The categories and differences of unwise, unethical, and unlawful political actions. 📍 [00:55:00] – The balance between justice, kindness, and humility in political engagement. 📍 [01:00:00] – The After Party initiative: A Christian approach to politics focused on values rather than policy. 💬 Featured Quotes 🔹 "You don't know who you truly are until your values are tested." – David French 🔹 "If we focus on the relational, we can have better conversations even across deep differences." – Corey Nathan 🔹 "Justice, kindness, and humility—if you're missing one, you're doing it wrong." – David French 🔹 "The United States has a history of shifting without repenting. We just move on." – David French 📚 Resources Mentioned David French’s Writing: New York Times David’s Book: Divided We Fall The After Party Initiative – More Info Advisory Opinions Podcast (with Sarah Isgur & David French) – Listen Here 📣 Call to Action If you found this conversation insightful, please: ✅ Subscribe to Talkin' Politics & Religion Without Killin' Each Other on your favorite podcast platform. ✅ Leave a review on Apple Podcasts, Spotify, or wherever you listen: ratethispodcast.com/goodfaithpolitics ✅ Support the show on Patreon: patreon.com/politicsandreligion ✅ Watch the full conversation and subscribe on YouTube: youtube.com/@politicsandreligion 🔗 Connect With Us on Social Media @coreysnathan: Bluesky LinkedIn Instagram Threads Facebook Substack David French: 🔗 Twitter | BlueSky | New York Times Our Sponsors Meza Wealth Management: www.mezawealth.com Prolux Autogroup: www.proluxautogroup.com or www.granadahillsairporttransportation.com Let’s keep talking politics and religion—with gentleness and respect. 🎙️💡…

Rare Kidney Disease Show «
Getting Ahead of IgAN: A New Treatment Paradigm for Disease Control ft. Dr. Brad Rovin : 1

about a year ago 16:15

MP3•Episode home

Overview:

In this episode of the Rare Kidney Disease Show, Dr. Rovin, Professor of Internal Medicine and Pathology at Ohio State University and chair of the RKD Scientific Network and Podcast, discusses advances in the management of IgAN through a patient case study.

“IgAN progresses more often than we thought and progresses even in patients with low levels of proteinuria.”
“We continue to strive for greater improvements.”
“Approaching IgAN with targeted therapies can affect different aspects of IgAN pathogenesis.”

Key Takeaways:

Understanding the Underlying IgAN pathophysiology: Highlight the 4-Hit Hypothesis and the intricate disease mechanism (4:27)
IgAN Case Study Introduction (6:57)
Treatment Initiation (8:26)
Management of Progression: Question the outcomes of initial intervention for this patient (9:50)
Foundational Therapy: Optimization for improved outcomes (10:24)
Maintenance Options: Explore available therapies to sustain treatment effectiveness (11:05)
Postulated Algorithm: Discover an algorithm for inflammation management and proteinuria reduction (11:49)
Closing Remarks: Gain insight into future episodes (14:10)

5 episodes

Rare Kidney Disease Show

Getting Ahead of IgAN: A New Treatment Paradigm for Disease Control ft. Dr. Brad Rovin : 1

Rare Kidney Disease Show

published about a year ago

MP3•Episode home

“IgAN progresses more often than we thought and progresses even in patients with low levels of proteinuria.”
“We continue to strive for greater improvements.”
“Approaching IgAN with targeted therapies can affect different aspects of IgAN pathogenesis.”

Key Takeaways:

Understanding the Underlying IgAN pathophysiology: Highlight the 4-Hit Hypothesis and the intricate disease mechanism (4:27)
IgAN Case Study Introduction (6:57)
Treatment Initiation (8:26)
Management of Progression: Question the outcomes of initial intervention for this patient (9:50)
Foundational Therapy: Optimization for improved outcomes (10:24)
Maintenance Options: Explore available therapies to sustain treatment effectiveness (11:05)
Postulated Algorithm: Discover an algorithm for inflammation management and proteinuria reduction (11:49)
Closing Remarks: Gain insight into future episodes (14:10)

5 episodes

#Fitness #Podcasting Education #Medicine #Travere Therapeutics #Rare Kidney Disease #RKD #Travers #Igans #Fsgs

All episodes

Rare Kidney Disease Show

1
ASN Update - Sparsentan Redefining IgAN Treatment 19:07

10 weeks ago19:07

19:07

In this episode of the Rare Kidney Disease Show, a panel of nephrology experts explore the latest data on sparsentan, as presented at ASN Kidney Week 2024. Dr. Hiddo Heerspink presents a post hoc analysis of the PROTECT trial comprised of patients who achieved complete proteinuria remission. Dr. Chee Kay Cheung shares interim data from the SPARTAN study on sparsentan therapy in treatment-naïve patients with IgA nephropathy. Lastly, Dr. Bruce Hendry discusses combination treatment of sparsentan with SGLT2i in the SPARTACUS study. These discussions are introduced by Dr. Edgar Lerma, who offers his insights into the possible clinical implications of these data.…

Rare Kidney Disease Show

1
Rethinking IgAN: A Different Perspective from Community Nephrologists : 4 15:58

32 weeks ago15:58

15:58

Luis Velez, MD is a board-certified community nephrologist in San Antonio, TX with expertise in hypertension and glomerular disorders. Jessica Coleman, MD is a board-certified community nephrologist practicing between Savanah, GA and Charleston, SC with expertise in hypertension and glomerular disorders. In this episode, Drs Velez and Coleman discuss management of IgAN patients from the viewpoint of community nephrologists. They discuss the evolution in their management of IgAN, highlighting the availability of new data such as RaDaR as a key driver of change. With greater awareness of the role of proteinuria, they advocate for early and aggressive treatment to avoid long term complications of IgAN. Key Quotes: “RaDaR taught me that the traditional way of looking at IgA nephropathy is wrong. We realized this is a disease state that absolutely can progress and can progress more rapidly than what we initially appreciated and certainly at a younger age in these patients . (02:25) “When we look at patients with proteinuria, even just 0.5 g/d, a third of patients under 40 are going to progress to end stage kidney disease in ten years [RaDaR].” (04:30) “With the RaDaR data, we see levels of proteinuria 0.5 -0.8 g/d still being significant markers for disease progression.” (08:56) Key Takeaways: IgAN is not a benign disease Proteinuria is the most important prognostic indicator of disease progression in IgA Nephropathy HCPs should be targeting lower proteinuria goals to achieve complete remission <0.3 g/d The updated KDIGO Guidelines should support clinicians’ decisions to target complete remission…

Rare Kidney Disease Show

1
The Role of Endothelin in IgAN, ft. Dr. Donald Kohan : 3 17:25

39 weeks ago17:25

17:25

Episode Overview: Donald Kohan, PhD is an Emeritus Professor at the University of Utah Health with expertise in endothelin receptors, sodium transporters, and the renin-angiotensin-aldosterone system in chronic kidney disease. In this episode, Professor Kohan provides an overview of the endothelin system and how it relates to the pathophysiology of chronic kidney disease and IgA nephropathy specifically. Key Quotes: “Endothelin 1 is a really unusual molecule. It's highly stable because it has 2 interchain disulfide bonds that resist degradation. It's extremely potent having about 10 fold higher potency than any other known vasoactive factor.” “Angiotensin and ET-1 cause their effects through different pathways.” “Angiotensin stimulates transient calcium release, which causes more short-term contraction and other effects. While endothelin 1 stimulates more sustained calcium release, which then elicits longer lasting pathophysiologic effects.” Key Takeaways: (04:41) Endothelin-1 acts via ETA receptors to cause vasoconstriction, fibrosis, cell proliferation and other effects that promote chronic kidney disease (06:15) The endothelin and renin-angiotensin systems interact, forming a vicious cycle that worsens kidney injury (12:19) In IgA nephropathy models, combined ETA + angiotensin receptor blockade with sparsentan reduced proteinuria and kidney injury more than angiotensin blockade alone…

Rare Kidney Disease Show

1
Unmet Needs in IgAN: Burden of Disease & Long-Term Impact on Patients ft. Dr. Jonathan Barratt : 2 15:44

48 weeks ago15:44

15:44

Overview: In this episode of the Rare Kidney Disease Show, Professor Jonathan Barratt discusses the need to take a long-term approach when managing IgA nephropathy patients. He presents data from the UK National Registry of Rare Kidney Diseases (RaDaR). During this recording you will hear Professor Barratt discussing the continued risk of progression to end stage renal disease even in patients with proteinuria of less than 1g/day, the current threshold of high risk as per KDIGO guidelines. The data from the UK has been reinforced by recent database studies and these will also be discussed by Professor Barratt. Key Quotes: "If you have IgA Nephropathy and you're diagnosed as a child, half of those children have developed kidney failure at 20 years." "We need to be thinking, what is it like for that patient in front of us being 50 or 60, not necessarily what's going to happen in the next five or ten years." "If we don't think the longer term, we're going to under-treat and not serve our patients well." Key Takeaways: IgA nephropathy patients often have decades of life ahead of them, so physicians should focus on minimizing lifetime risk of kidney failure rather than short-term outcomes (00:02:11) RaDaR data shows high rates of kidney failure among IgA nephropathy patients in the UK, even those diagnosed and treated as children (00:04:05) Per the RaDaR publication, an eGFR decline of <1 ml/min per 1.73 m2 per year must be the target if patients are to avoid kidney failure (00:06:48) In the UK, 1 in 4 IgA nephropathy patients with 0.5-1 g/day proteinuria reach ESRD within 10 years (00:08:23) Recent US database searches confirm high rates of CKD progression and kidney failure in IgA nephropathy patients, even those with lower proteinuria levels (00:13:20)…

Rare Kidney Disease Show

1
Getting Ahead of IgAN: A New Treatment Paradigm for Disease Control ft. Dr. Brad Rovin : 1 16:15

1 year ago16:15